LRRK2 activation in idiopathic Parkinson’s disease-Reference-Cited by-同舟云学术

LRRK2 activation in idiopathic Parkinson’s disease

Published:2018-07-25 Issue:451 Volume:10 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Di Maio Roberto¹²³^ORCID,Hoffman Eric K.¹²^ORCID,Rocha Emily M.¹²,Keeney Matthew T.¹²^ORCID,Sanders Laurie H.¹²⁴^ORCID,De Miranda Briana R.¹²^ORCID,Zharikov Alevtina¹²^ORCID,Van Laar Amber¹²^ORCID,Stepan Antonia F.⁵,Lanz Thomas A.⁵,Kofler Julia K.⁶^ORCID,Burton Edward A.¹²⁷^ORCID,Alessi Dario R.⁸^ORCID,Hastings Teresa G.¹²^ORCID,Greenamyre J. Timothy¹²⁷^ORCID

Affiliation:

1. Pittsburgh Institute for Neurodegenerative Diseases, University of Pittsburgh, Pittsburgh, PA 15213, USA.

2. Department of Neurology, University of Pittsburgh, Pittsburgh, PA 15213, USA.

3. Ri.MED Foundation, Palermo, Italy.

4. Department of Neurology, Duke University, Durham, NC 27710, USA.

5. Worldwide Medicinal Chemistry, Pfizer Worldwide Research and Development, Cambridge, MA 02139, USA.

6. Department of Pathology, University of Pittsburgh, Pittsburgh, PA 15213, USA.

7. Geriatric Research, Education and Clinical Center, VA Pittsburgh Healthcare System, Pittsburgh, PA 15240, USA.

8. MRC Protein Phosphorylation and Ubiquitylation Units, University of Dundee, Dundee, Scotland.

Abstract

Wild-type LRRK2 is activated in nigrostriatal dopamine neurons in idiopathic Parkinson’s disease and plays a pathogenic role in this neurodegenerative disorder.

Funder

National Institute on Aging

National Institute of Neurological Disorders and Stroke

National Institute of Environmental Health Sciences

Michael J. Fox Foundation for Parkinson’s Research

American Parkinson Disease Association

Medical Research Council

The Blechman Foundation

friends and family of Sean Logan

Ri.Med Foundation

Publisher

American Association for the Advancement of Science (AAAS)